Ortho Biotech Oncology Research & Development Unites Johnson & Johnson Biopharmaceutical Oncology ...(deletion of upstream tumor suppressors.H...)

Date:4/11/2008

deletion of upstream tumor suppressors. Hdm2 over-expression induces tumor formation, and Hdm2 levels correlate with sporadic tumor incidence in humans(i). Hdm2 promotes tumor cell proliferation by associating with cell cycle regulatory proteins, modulating their activity and stability. Key examples include p53, p73, E2F1 and HIF1a(ii),(iii). This positions the Hdm2 protein as an attractive target for the development of anti-cancer agents.

Histone Deacetylase (HDAC)

DNA in chromatin is wound around proteins called histones. HDACs are a family of enzymes that influence gene expression through selective regulation of chromatin structure. Inappropriate gene expressions, due to changes in chromatin structure, are a hallmark of cancer. HDAC inhibitors aim to normalize chromatin structure, thereby restoring the activity of genes which inhibit proliferation, angiogenesis and metastasis(iv).

c-Met Receptor Tyrosine Kinase (c-Met RTK)

Receptor tyrosine kinases (RTKs) are cell surface receptors that regulate many key processes including invasive growth and cell survival. The c-Met RTK pathway has been shown to be specifically important in regulation of cell migration and invasion, cell proliferation, survival and angiogenesis. Deregulation of c-Met RTKs has been implicated in the development and progression of numerous human cancers. The c-Met RTK inhibitors prevent receptor activation and thus inhibit tumor cell development and metastasis(v),(vi),(vii),(viii).

About ORD

Ortho Biotech Oncology Research & Development (ORD) is a new research and development organization dedicated to oncology, hematology and supportive care. ORD partners closely with Ortho Biotech Products, L.P. and Janssen-Cilag companies worldwide to bring oncology treatments and supportive medicines to patients around the world. ORD is headquartered in Raritan, N.J., and has facilities throughout Europe and the United States.

(This press release contains "forw
'/>"/>

SOURCE Ortho Biotech Copyright©2008 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4 5
Related biology technology :

1. Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa)
2. Osteotech to Present at the Canaccord Adams Small-Cap Orthopedics Conference in San Francisco
3. ROBODOC(R) Emerges as a Curexo Technology Company at Upcoming Orthopaedic Surgeons Conference in San Francisco
4. NuVasive to Present at Canaccord Adams Small-Cap Orthopedics Conference
5. SyntheMed to Present at Canaccord Adams Small-Cap Orthopedics Conference
6. Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents
7. Symmetry Medical to Present at Canaccord Adams Small-Cap Orthopedics Conference
8. Kensey Nash to Present at the Canaccord Adams Small-Cap Orthopedics Conference
9. Barr and Ortho Womens Health & Urology in Discussions to Settle ORTHO TRI-CYCLEN(R) LO Patent Litigation
10. Progentix Orthobiology B.V. Closes Series A Financing Round
11. Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa) Label Reflects Recommendations from Recent FDA Advisory Committee Meetings